Emerging human and zoonotic RNA viruses including SARS-CoV cause significant global morbidity, mortality, and social disruption. The current model for RNA virus host-species movement, adaptation, evolution, disease, and resistance to vaccines and antivirals is that they generate vast diversity of related mutants around the central consensus genome, also referred to as quasispecies diversity or """"""""mutant swarms"""""""". This allows for rapid selection of adaptive change, and until recently was thought to result solely from the action of RNA- dependent RNA polymerases with low fidelity (high basal mutation rate) and no error repair - proofreading - during RNA synthesis. Coronaviruses (CoVs) are broadly represented in humans, bats, and other mammals and avian species, and are adept at host-species movement and adaptation, as demonstrated by SARS-CoV and the novel HCoV-EMC/2012. CoVs contain the largest positive-strand RNA genomes, up to 32 kb, posing unique challenges to models of intrinsic low-fidelity replication. CoVs encode a DEDDh family 3'-to-5'exoribonuclease in nonstructural protein 14 (nsp14-ExoN), and inactivating mutations in ExoN (ExoN-) of murine hepatitis virus (MHV) and SARS-CoV result in viable mutator phenotypes (20-fold decreased fidelity) in vitro and in vivo. CoV ExoN- mutator viruses manifest decreased fitness compared to ExoN+ (WT) viruses, are sensitive to RNA mutagens, and are stably attenuated in mouse models of lethal SARS-CoV infection. Thus, nsp14-ExoN is likely the first known RNA virus proofreading exonuclease, and is critically involved in virus replication, fitness, and pathogenesis. However, how it regulates fidelity is unknown. Nsp14-ExoN is a distinct protein from the RNA dependent RNA polymerase (nsp12) and also has been shown to have enhanced exoribonuclease activity in vitro by interactions with nsp10. The contributions of these and other CoV proteins to fidelity regulation also is undetermined. Experiments in this proposal will test the hypothesis that CoVs encode multiple proteins, including nsp14-ExoN, nsp12, and nsp10, that together regulate replication fidelity.
The specific aims of the proposal are: 1) To define fidelity determinants in nsp14 and the impact on viral fitness and RNA synthesis;2) To identify proteins and determinants within the CoV fidelity complex;and 3) To determine the effect of altered fidelity on in vivo replication and pathogenesis. The proposed aims build on the complementary strengths and collaborations of the Denison and Baric labs in CoV (MHV and SARS-CoV) reverse genetics, replicase protein mutagenesis and functions, pathogenesis, immune response, and synthetic genomics. The results of the proposed experiments will identify fidelity determinants critical for replication, pathogenesis and virulence, define the range of tolerated fidelity, and identify novel approaches for CoV attenuation and inhibition.

Public Health Relevance

Coronaviruses (CoVs) including SARS-CoV encode a novel exoribonuclease (ExoN) activity that is required for replication fidelity, a process unprecedented in RNA virus biology. We will identify key determinants in ExoN and other replicase proteins that regulate CoV replication fidelity, and will determine the role of fidelity in CoV replication and pathogenesis. Results from these experiments will increase our understanding of how CoVs adapt to new hosts, will establish fidelity-based strategies for CoV attenuation, and will identify novel targets for inhibition of replication fidelity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI108197-02
Application #
8711280
Study Section
Virology - B Study Section (VIRB)
Program Officer
Stemmy, Erik J
Project Start
2013-08-01
Project End
2017-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
2
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Pediatrics
Type
Schools of Medicine
DUNS #
City
Nashville
State
TN
Country
United States
Zip Code
37212
Graham, Rachel L; Deming, Damon J; Deming, Meagan E et al. (2018) Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform. Commun Biol 1:179
Menachery, Vineet D; Gralinski, Lisa E; Mitchell, Hugh D et al. (2018) Combination Attenuation Offers Strategy for Live Attenuated Coronavirus Vaccines. J Virol 92:
Athmer, Jeremiah; Fehr, Anthony R; Grunewald, Matthew E et al. (2018) Selective Packaging in Murine Coronavirus Promotes Virulence by Limiting Type I Interferon Responses. MBio 9:
Nakagawa, Keisuke; Narayanan, Krishna; Wada, Masami et al. (2018) The Endonucleolytic RNA Cleavage Function of nsp1 of Middle East Respiratory Syndrome Coronavirus Promotes the Production of Infectious Virus Particles in Specific Human Cell Lines. J Virol 92:
Case, James Brett; Li, Yize; Elliott, Ruth et al. (2018) Murine Hepatitis Virus nsp14 Exoribonuclease Activity Is Required for Resistance to Innate Immunity. J Virol 92:
Agostini, Maria L; Andres, Erica L; Sims, Amy C et al. (2018) Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. MBio 9:
Sheahan, Timothy P; Sims, Amy C; Graham, Rachel L et al. (2017) Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 9:
Athmer, Jeremiah; Fehr, Anthony R; Grunewald, Matthew et al. (2017) In Situ Tagged nsp15 Reveals Interactions with Coronavirus Replication/Transcription Complex-Associated Proteins. MBio 8:
Graepel, Kevin W; Lu, Xiaotao; Case, James Brett et al. (2017) Proofreading-Deficient Coronaviruses Adapt for Increased Fitness over Long-Term Passage without Reversion of Exoribonuclease-Inactivating Mutations. MBio 8:
Case, James Brett; Ashbrook, Alison W; Dermody, Terence S et al. (2016) Mutagenesis of S-Adenosyl-l-Methionine-Binding Residues in Coronavirus nsp14 N7-Methyltransferase Demonstrates Differing Requirements for Genome Translation and Resistance to Innate Immunity. J Virol 90:7248-7256

Showing the most recent 10 out of 23 publications